Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY2R | P49146 | 8/20 | 0.67 |
| ▸ | NPY4R | P50391 | 8/20 | 0.67 |
| ▸ | NPY5R | Q15761 | 8/20 | 0.67 |
| ▸ | NPY1R | P25929 | 6/20 | 0.67 |
| ▸ | CALCR | P30988 | 3/20 | 0.62 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.62 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.62 |
| ▸ | GLP1R | P43220 | 4/20 | 0.61 |
| ▸ | TFPI | P10646 | 3/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31146614 | 0.92 | NPY2R (0.73) | NPY2RNPY4RNPY5RNPY1RCALCR | |
| SCHEMBL30495784 | 0.91 | NPY2R (0.70) | NPY2RNPY4RNPY5RNPY1RCALCR | |
| SCHEMBL30578732 | 0.91 | NPY2R (0.74) | NPY2RNPY4RNPY5RNPY1RCALCR | |
| SCHEMBL29360287 | 0.90 | NPY2R (0.71) | NPY2RNPY4RNPY5RNPY1RCALCR | |
| SCHEMBL30804648 | 0.90 | NPY2R (0.63) | NPY2RNPY4RNPY5RNPY1RCALCR | |
| SCHEMBL31182717 | 0.89 | CALCR (0.68) | NPY2RNPY4RNPY5RNPY1RCALCR | |
| SCHEMBL30495665 | 0.89 | CALCR (0.65) | NPY2RNPY4RNPY5RNPY1RCALCR | |
| SCHEMBL30658400 | 0.89 | NPY2R (0.63) | NPY2RNPY4RNPY5RNPY1RCALCR | |
| SCHEMBL31182942 | 0.89 | NPY2R (0.59) | NPY2RNPY4RNPY5RNPY1RCALCR | |
| SCHEMBL30658245 | 0.89 | CALCR (0.71) | NPY2RNPY4RNPY5RNPY1RCALCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11801240-B2 | Combination therapies and uses thereof | TESARO, INC. (US) | 2023-10-31 | — | — | US | claimed |
| US-12297184-B2 | Niraparib salts | TESARO, INC. (US) | 2025-05-13 | — | — | US | disclosed |
| US-20240082231-A1 | NIRAPARIB FORMULATIONS | TESARO, INC. | 2024-03-14 | — | — | US | disclosed |
| US-11801240-B2 | Combination therapies and uses thereof | TESARO, INC. (US) | 2023-10-31 | — | — | US | disclosed |
| US-11730725-B2 | Niraparib formulations | TESARO, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-20220249598-A1 | COMPOSITIONS TARGETING SPERM CALCINEURIN | KENT STATE UNIVERSITY (US) | 2022-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11801240-B2 | Combination therapies and uses thereof | PARP2, PARP3, PARP4 | NPY2R 3689/4885NPY4R 3387/4885NPY5R 3828/4885 |
| US-12297184-B2 | Niraparib salts | PARP2, PARP1, TOP2B | NPY2R 4214/4885NPY4R 4580/4885NPY5R 3730/4885 |
| US-11730725-B2 | Niraparib formulations | PARP2, PARP1, PARP9 | NPY2R 2917/4885NPY4R 4054/4885NPY5R 1023/4885 |
| US-20240082231-A1 | NIRAPARIB FORMULATIONS | PARP2, PARP1, PARP9 | NPY2R 2917/4885NPY4R 4054/4885NPY5R 1023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.